-
Dec 9, 2024 | 
indibloghub.com | Sanobar Syed
Author: Sanobar Syed, Associate Director, BeigeneIn the increasing uncertainties and volatile market, pharmaceutical companies have to rethink their approach to forecasting in oncology. When projections are misaligned, pharma companies will have to answer shareholders. But when forecasters get it right, manufacturers can optimise resources to fit the opportunity and produce plans that deliver innovative medicines to patients who need them.
-
Mar 6, 2024 | 
medtechintelligence.com | Sanobar Syed
Forecasting is a vital activity that supports a range of key business decisions across a broad range of stakeholders in pharma and medtech. And it is not just about crunching numbers; it’s about interpreting data effectively and using it to make informed decisions promptly.
-
Feb 27, 2024 | 
insights.omnia-health.com | Sanobar Syed
The year 2023 has just paved the way for a new future. We have almost fully recovered from the aftermath of the unprecedented pandemic and in the past few years, pharma companies have realised the importance of data. To quote British mathematician and entrepreneur Clive Humby, data is indeed the ‘new oil for pharma companies’ and much more than that.
-
Aug 30, 2023 | 
insights.omnia-health.com | Sanobar Syed
With the ever-changing cell and gene therapy (CGT) market dynamics, it is increasingly complex to forecast and enable decision-making in the field but the markets in which CGT operates have a solid influence. In a broader market upon which to spread the development costs, such as oncology, where there is usually a larger patient population, therapies can hit a lower price point.
-
Aug 2, 2023 | 
outsourcedpharma.com | Louis Garguilo |Sanobar Syed |Ruijin Song |Andrew Walsh
By Sanobar Syed, M.Sc., MBA Is reshoring or nearshoring right for your organization? It's important to undertake rigorous internal assessments to arrive at a decision. Here are four key considerations. By Ruijin Song and Andrew Walsh ASTM E3106 emphasizes that cleaning agents and cleaning processes should not be adopted randomly, nor should they be chosen simply based on what has been used in the past.
-
Jun 20, 2023 | 
medtechintelligence.com | Sanobar Syed
Reaching new patients often requires expansion into new geographies, which requires accurate market research and forecasting to understand the local international market you are seeking to enter. To successfully conduct market research and forecasting in international markets, pharmaceutical and MedTech organizations need an in-depth understanding of the environment in which they are planning to operate, and this can be tricky as many lack reliable data intelligence.
-
May 3, 2023 | 
outsourcedpharma.com | Sanobar Syed |Louis Garguilo
Guest Column
| May 3, 2023
By Sanobar Syed, BeiGene
Product development of new generic molecules starts early in the life cycle of the originator product (at the time of market launch), so long-term planning is essential and mainly based on product patent expiries. For small molecule generics, the development and manufacturing processes are in most cases straightforward.
-
Apr 27, 2023 | 
cellandgene.com | Sanobar Syed
By Sanobar Syed, BeiGene
Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. Recognizing CGT’s potential, 16 of the world’s largest (by revenue) 20 biopharma companies now have CGT assets in their product portfolios. Yet most companies are moving cautiously — only two of the top 20 have CGT assets making up more than 20 percent of their pipelines.
-
Apr 14, 2023 | 
insights.omnia-health.com | Sanobar Syed
Strategic analytics and forecasting in oncology and rare diseases go beyond numbers, as each number is a patient, and each patient is a life. Oncology is a complicated but important pharma category to forecast with oncology assets becoming an increasingly critical part of company portfolios. Business strategies, forecasts and analytics are used for research and development, while new product portfolio planning requires different methodology and outputs than other functional areas.
-
Apr 13, 2023 | 
expresspharma.in | Sanobar Syed
The generic pharma industry has come a long way. Pharmaceutical forecasting and business analytics have come longer. The speed at which the industry is turning, even more after the COVID-19 aftermath, is nauseating. According to a Deloitte study, the cost to take a drug candidate from the discovery stage to market launch hit $2.3 billion—a $298 million rise from 2021.
